Hyperlipidemia - PACE-CME

Episodes 33-38 of 38

MinuteCE®
The LDL-c challenge in high cardiovascular risk - Integrating innovative therapies in clinical management
1.00 credit 4 episodes
- Kausik Ray, MBChB, MD, MPhil
- Lale Tokgözoğlu, MD
- Prof. dr. Fabrice Martens
- Erin Michos
1.00 credit 4 episodes
Novel oral pathways in LDL-C lowering therapy: The new promise of CETPi
Novel oral pathways in LDL-C lowering therapy: The new promise of CETPi
MinuteCE®
Novel oral pathways in LDL-C lowering therapy: The new promise of CETPi
1.00 program credit
- Erin Michos
1.00 program credit
New insights on CETP inhibition from genetic research and clinical trials
New insights on CETP inhibition from genetic research and clinical trials
MinuteCE®
New insights on CETP inhibition from genetic research and clinical trials
1.00 program credit
- Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
1.00 program credit
MinuteCE®
Role of CETP inhibitors in cardiovascular risk reduction - Will lessons from the past lead to future success?
1.00 credit 3 episodes
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
- Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
- Roxana Mehran, MD
1.00 credit 3 episodes
Unmet needs in lowering LDL-c
Unmet needs in lowering LDL-c
MinuteCE®
Unmet needs in lowering LDL-c
1.00 program credit
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
1.00 program credit
Exploring the role of a novel CETP inhibitor in lipid management
Exploring the role of a novel CETP inhibitor in lipid management
MinuteCE®
Exploring the role of a novel CETP inhibitor in lipid management
1.00 program credit
- Roxana Mehran, MD
1.00 program credit

Previous
1
2
3
Next

3/3